Massachusetts study finds a third of sample have COVID-19 antibodies

Several studies suggest that COVID-19 is far more prevalent — and correspondingly less deadly — than has been widely assumed

massachusetts
A coronavirus testing facility in Massachusetts
Share
Text
Text Size
Small
Medium
Large
Line Spacing
Small
Normal
Large

Last week I reported here a Stanford University study which found that infection with SARS-CoV-2 — the virus which causes COVID-19 — could be over 50 times as widespread in one Californian county than official figures suggested.
Now comes yet another piece of evidence suggesting similarly huge under-reporting of cases. Researchers from Massachusetts General Hospital performed antibody tests on 200 random members of the public they found on the streets of Chelsea, near Boston. They discovered that 32 percent of them had antibodies suggesting they had already been infected with the virus — official figures show that…

Last week I reported here a Stanford University study which found that infection with SARS-CoV-2 — the virus which causes COVID-19 — could be over 50 times as widespread in one Californian county than official figures suggested.

Now comes yet another piece of evidence suggesting similarly huge under-reporting of cases. Researchers from Massachusetts General Hospital performed antibody tests on 200 random members of the public they found on the streets of Chelsea, near Boston. They discovered that 32 percent of them had antibodies suggesting they had already been infected with the virus — official figures show that just two percent of the local population had been confirmed to be suffering from the virus.

The usual caveats apply here as with much of coronavirus research at present. It is not a peer-reviewed study. It included only 200 people and the sample cannot be considered representative of the population of Massachusetts, or even Chelsea. The test used has not been approved by the Food and Drug Administration, although it is considered good enough for the hospital. But it is an indication of what we can perhaps expect to find when we do have the results of large-scale community tests. A lot of evidence is now pointing in the same direction: that COVID-19 has spread far further and more easily than anyone initially imagined, but that it is correspondingly less deadly.

In addition to the Stanford and Massachusetts studies, we also have a study from the German town of Gangelt, where 15 percent of the population were found to have had the virus. Yesterday, I reported that a forthcoming study into the prevalence of the infection in Stockholm will — according to Sweden’s former chief epidemiologist Johan Giesecke – show an infection rate in the order of 10 to 30 percent.

***
Get three months’ free access to The Spectator USA website —
then just $3.99/month. Subscribe here

***

These all matter because they suggest that COVID-19 is far more prevalent — and correspondingly less deadly — than has been widely assumed. Moreover, they give credence to the UK government’s original policy — swiftly dropped upon the publication of the Imperial College paper on March 16 — of relying on herd immunity to get us out of the coronavirus crisis. No study has yet indicated that 60 percent of a country’s population is infected with SARS-Cov-2 — the proportion that chief scientific adviser Sir Patrick Vallance suggested would be required to achieve herd immunity — but they do suggest that some parts of the world might be well on the way.

It ought to be emphasized that still there is something inadequate about this body of evidence — the studies are all quite small — but it underlines just how much we need community antibody tests to inform us of what path to take from here.

This article was originally published on The Spectator s UK website.